Buy AbbVie (ABBV) stock? See more on its 2025 EPS growth outlook from Skyrizi/Rinvoq, valuation at 14.4x FY27, key risks, and ...

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique legal challenge, the Dutch Pharmaceutical ...

AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...

AbbVie signed a non-exclusive licensing deal with Pfizer for its Humira biosimilar, Nasdaq reports. 1. Pfizer can launch its Humira biosimilar in the U.S. on Nov. 20, 2023. In Europe, Pfizer can ...

A federal judge ruled that AbbVie didn’t break antitrust laws by settling patent lawsuits regarding its blockbuster rheumatoid arthritis drug, Humira, STAT reported. A class-action lawsuit was filed ...

AbbVie's valuation and dividend program seal the deal.

AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw ...

A class action lawsuit was filed against AbbVie for allegedly using patent thickets and colluding with biosimilar drugmakers to maintain monopoly for its blockbuster rheumatoid arthritis drug Humira, ...

VIRGINIA--(BUSINESS WIRE)--Alvotech today filed a federal lawsuit (Case 1:21-cv-00589) seeking to end the monopoly that pharmaceutical giant AbbVie has long-maintained on the adalimumab market, sold ...